GlassScriptPhysician profile
Patrick Winston Nugent
NPI 1962048702
$1,946.12
in general payments reported to CMS, 2019-2025
23 companies · $1,137 in 2025
The $1,137 reported for 2025 was more than what 87% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $35.44 · 2022: $58.84 · 2023: $370 · 2024: $345 · 2025: $1,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.84 |
| Education | $168.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $492.43 | 2024-2025 | |
| Daiichi Sankyo INC. | $239.04 | 2024-2025 | Vanflyta, Datroway, Enhertu |
| Incyte Corporation | $165.71 | 2022-2023 | Jakafi |
| Novocure INC. | $131.70 | 2025 | Optune Gio |
| Regeneron Healthcare Solutions, INC. | $124.81 | 2025 | Lynozyfic |
| Eisai INC. | $121.87 | 2025 | |
| Astellas Pharma US INC | $101.91 | 2023 | Cresemba |
| Sobi, INC | $76.23 | 2024-2025 | |
| Genzyme Corporation | $68.44 | 2025 | |
| Janssen Biotech, INC. | $58.14 | 2024-2025 | Tecvayli, Darzalex, Talvey |
| Pfizer INC. | $54.51 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $52.87 | 2024-2025 | Enhertu, Lynparza |
| Adaptive Biotechnologies Corporation | $46.89 | 2023 | Clonoseq |
| Genentech USA, INC. | $43.31 | 2023-2024 | Columvi, Polivy, Lunsumio |
| Ipsen Biopharmaceuticals, INC | $20.81 | 2024 | Tazverik |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adc Therapeutics America, INC. | $20.61 | 2024 | |
| Genmab U.S., INC. | $20.02 | 2023 | Epkinly |
| Abbvie INC. | $18.61 | 2023 | |
| Agios Pharmaceuticals, INC. | $18.13 | 2022 | |
| Alnylam Pharmaceuticals INC. | $17.75 | 2021 | |
| Glaxosmithkline, LLC. | $17.69 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.48 | 2023 | Ninlaro |
| Beone Medicines USA, INC. | $17.16 | 2025 | Tevimbra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Nugent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.